Open Nav

KIYATEC

  • Matt Gevaert, KIYATEC

Investment

  • Date:Thursday, October 18
  • Time:10:30 AM - 10:45 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Wasted time is the enemy of cancer patients. KIYATEC’s mission is to change the future of cancer care by accurately predicting patient-specific response and non-response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible – making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today’s and tomorrow’s therapies.
  • Company Website:http://kiyatec.com/
  • Company HQ City:Greenville
  • Company HQ Country:United States
  • Company HQ State:South Carolina       
  • CEO/Top Company Official:Matt Gevaert, CEO
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development :Test to accurately predict patient-specific response and non-response before drug treatment begins
  • Development Phase of Primary Product:Other/Not Applicable
  • Additional Information/Comments:Our high credibility in oncology is demonstrated by our co-location with the cancer institute inside the Greenville Health System (SC), and additional clinical relationships with the Mayo Clinic (Rochester, MN) and Inova (Falls Church, VA) as well as competitively awarded contracts with top pharma companies and the US NCI (National Cancer Institute). Based on excellent data from our clinical pilot, we are currently enrolling on a larger clinical study that supports our lead products in ovarian cancer and GBM: "3D-Prediction of Patient-Specific Response (3D-PREDICT)" ClinicalTrials.gov Identifier: NCT03561207.
  • Previous and Current Investors:Inova Strategic Investments, VentureSouth, AIM Group, Nexus Medical Partners
  • Total Amount Raised to Date, In All Rounds:$9M
Speakers
Matt Gevaert
KIYATEC
Back